Letter from the CEO: Dr. B in 2022
We’ve come a long way since Dr. B first launched at the height of the Covid-19 crisis last year. When vaccines were first released, we saw so many desperately-needed shots go to waste due to last-minute appointment cancellations and fluctuating supply. Our team set out to build a solution and ultimately offered vaccines to over one million people across 37 states in partnership with 700+ healthcare providers.
Now that vaccines are broadly available, we’re focusing on a new challenge: reducing health inequity by making sure everyone can access the prescriptions they need. This starts with at-home Covid-19 treatments.
In keeping with our original mission, I’m proud to announce that Dr. B is now a convenient way to get prescriptions for oral Covid-19 antivirals.
We're starting with Paxlovid, one of the treatments that has received FDA emergency use authorization. We've also added Molnupiravir (Lagevrio), another at-home antiviral that has been approved for emergency use by the FDA.
As part of our early-stage testing for this new offering, consultations for Paxlovid and Molnupiravir prescriptions are currently available at no cost for New York, California and Florida residents While prescription consultations on Dr. B will always be free for people who qualify based on need, we’ll eventually charge a small doctor consultation fee as we move into other states.
In addition to Covid-19 treatments, I’m also excited to announce that our new online service will focus on expanding access to a wide range of everyday prescriptions. To get an online prescription, you'll complete an online health assessment which is reviewed by a board certified doctor. If a prescription is appropriate, it will be sent to the pharmacy of your choice.
Stay tuned for more updates as we move work to make healthcare better and more equitable for everyone. Be well.
Cyrus Massoumi, CEO & Founder of Dr. B